Cargando…

Aza-BODIPY based carbonic anhydrase IX: Strategy to overcome hypoxia limitation in photodynamic therapy

Hypoxia caused by photodynamic therapy (PDT) is a major hurdle to cancer treatment since it can promote recurrence and progression by activating angiogenic factors, lowering therapeutic efficacy dramatically. In this work, AZB-I-CAIX(2) was developed as a carbonic anhydrase IX (CAIX)-targeting NIR p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pewklang, Thitima, Chansaenpak, Kantapat, Bakar, Siti Nursyahirah, Lai, Rung-Yi, Kue, Chin Siang, Kamkaew, Anyanee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666899/
https://www.ncbi.nlm.nih.gov/pubmed/36405312
http://dx.doi.org/10.3389/fchem.2022.1015883
_version_ 1784831604820017152
author Pewklang, Thitima
Chansaenpak, Kantapat
Bakar, Siti Nursyahirah
Lai, Rung-Yi
Kue, Chin Siang
Kamkaew, Anyanee
author_facet Pewklang, Thitima
Chansaenpak, Kantapat
Bakar, Siti Nursyahirah
Lai, Rung-Yi
Kue, Chin Siang
Kamkaew, Anyanee
author_sort Pewklang, Thitima
collection PubMed
description Hypoxia caused by photodynamic therapy (PDT) is a major hurdle to cancer treatment since it can promote recurrence and progression by activating angiogenic factors, lowering therapeutic efficacy dramatically. In this work, AZB-I-CAIX(2) was developed as a carbonic anhydrase IX (CAIX)-targeting NIR photosensitizer that can overcome the challenge by utilizing a combination of CAIX knockdown and PDT. AZB-I-CAIX(2) showed a specific affinity to CAIX-expressed cancer cells and enhanced photocytotoxicity compared to AZB-I-control (the molecule without acetazolamide). Moreover, selective detection and effective cell cytotoxicity of AZB-I-CAIX(2) by PDT in hypoxic CAIX-expressed murine cancer cells were achieved. Essentially, AZB-I-CAIX(2) could minimize tumor size in the tumor-bearing mice compared to that in the control groups. The results suggested that AZB-I-CAIX(2) can improve therapeutic efficiency by preventing PDT-induced hypoxia through CAIX inhibition.
format Online
Article
Text
id pubmed-9666899
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96668992022-11-17 Aza-BODIPY based carbonic anhydrase IX: Strategy to overcome hypoxia limitation in photodynamic therapy Pewklang, Thitima Chansaenpak, Kantapat Bakar, Siti Nursyahirah Lai, Rung-Yi Kue, Chin Siang Kamkaew, Anyanee Front Chem Chemistry Hypoxia caused by photodynamic therapy (PDT) is a major hurdle to cancer treatment since it can promote recurrence and progression by activating angiogenic factors, lowering therapeutic efficacy dramatically. In this work, AZB-I-CAIX(2) was developed as a carbonic anhydrase IX (CAIX)-targeting NIR photosensitizer that can overcome the challenge by utilizing a combination of CAIX knockdown and PDT. AZB-I-CAIX(2) showed a specific affinity to CAIX-expressed cancer cells and enhanced photocytotoxicity compared to AZB-I-control (the molecule without acetazolamide). Moreover, selective detection and effective cell cytotoxicity of AZB-I-CAIX(2) by PDT in hypoxic CAIX-expressed murine cancer cells were achieved. Essentially, AZB-I-CAIX(2) could minimize tumor size in the tumor-bearing mice compared to that in the control groups. The results suggested that AZB-I-CAIX(2) can improve therapeutic efficiency by preventing PDT-induced hypoxia through CAIX inhibition. Frontiers Media S.A. 2022-11-02 /pmc/articles/PMC9666899/ /pubmed/36405312 http://dx.doi.org/10.3389/fchem.2022.1015883 Text en Copyright © 2022 Pewklang, Chansaenpak, Bakar, Lai, Kue and Kamkaew. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Pewklang, Thitima
Chansaenpak, Kantapat
Bakar, Siti Nursyahirah
Lai, Rung-Yi
Kue, Chin Siang
Kamkaew, Anyanee
Aza-BODIPY based carbonic anhydrase IX: Strategy to overcome hypoxia limitation in photodynamic therapy
title Aza-BODIPY based carbonic anhydrase IX: Strategy to overcome hypoxia limitation in photodynamic therapy
title_full Aza-BODIPY based carbonic anhydrase IX: Strategy to overcome hypoxia limitation in photodynamic therapy
title_fullStr Aza-BODIPY based carbonic anhydrase IX: Strategy to overcome hypoxia limitation in photodynamic therapy
title_full_unstemmed Aza-BODIPY based carbonic anhydrase IX: Strategy to overcome hypoxia limitation in photodynamic therapy
title_short Aza-BODIPY based carbonic anhydrase IX: Strategy to overcome hypoxia limitation in photodynamic therapy
title_sort aza-bodipy based carbonic anhydrase ix: strategy to overcome hypoxia limitation in photodynamic therapy
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666899/
https://www.ncbi.nlm.nih.gov/pubmed/36405312
http://dx.doi.org/10.3389/fchem.2022.1015883
work_keys_str_mv AT pewklangthitima azabodipybasedcarbonicanhydraseixstrategytoovercomehypoxialimitationinphotodynamictherapy
AT chansaenpakkantapat azabodipybasedcarbonicanhydraseixstrategytoovercomehypoxialimitationinphotodynamictherapy
AT bakarsitinursyahirah azabodipybasedcarbonicanhydraseixstrategytoovercomehypoxialimitationinphotodynamictherapy
AT lairungyi azabodipybasedcarbonicanhydraseixstrategytoovercomehypoxialimitationinphotodynamictherapy
AT kuechinsiang azabodipybasedcarbonicanhydraseixstrategytoovercomehypoxialimitationinphotodynamictherapy
AT kamkaewanyanee azabodipybasedcarbonicanhydraseixstrategytoovercomehypoxialimitationinphotodynamictherapy